Profile data is unavailable for this security.
About the company
Coloplast A/S is a Denmark-based company active within the healthcare sector. It is engaged in the development, marketing and sale of intimate healthcare products and services, targeting people with diseases of private and personal nature. Its operations are structured into four business areas: Ostomy Care offering products for people whose intestinal outlet has been rerouted through the abdominal wall, Continence Care products for people suffering from diseases of and damage to the urinary system, Urology Care products for people suffering from diseases of and damage to the kidneys, the urinary system or the male reproductive system and Wound & Skin Care for the treatment of chronic wounds and skin care products for prevention and treatment. The Company supplies products to hospitals, institutions as well as wholesalers and pharmacies.
- Revenue in DKK (TTM)27.03bn
- Net income in DKK5.05bn
- Incorporated1957
- Employees16.25k
- LocationColoplast A/SHoltedam 1-3HUMLEBAEK 3050DenmarkDNK
- Phone+45 49111111
- Fax+45 49111555
- Websitehttps://www.coloplast.dk/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ypsomed Holding AG | 4.94bn | 595.68m | 39.02bn | 2.60k | 65.52 | 7.84 | 32.29 | 7.90 | 5.45 | 5.45 | 45.20 | 45.56 | 0.5828 | 5.28 | 5.46 | 268,759.60 | 7.03 | 4.41 | 11.60 | 6.81 | 35.44 | 27.26 | 12.06 | 7.38 | 0.5060 | 13.12 | 0.3434 | 20.50 | 10.25 | 3.86 | 52.83 | 5.44 | 8.64 | 29.46 |
| Amplifon SpA | 17.60bn | 1.16bn | 39.23bn | 14.38k | 33.69 | 4.69 | 11.69 | 2.23 | 0.6898 | 0.6898 | 10.40 | 4.96 | 0.6255 | 20.32 | 10.83 | 164,118.00 | 4.13 | 4.31 | 6.24 | 5.81 | 23.55 | 59.01 | 6.61 | 7.28 | 0.4043 | 5.23 | 0.6064 | 34.26 | 6.65 | 10.66 | -12.21 | 9.08 | 12.68 | 15.68 |
| ConvaTec Group PLC | 15.75bn | 1.10bn | 43.55bn | 10.13k | 39.82 | 3.68 | 16.37 | 2.76 | 0.0595 | 0.0595 | 0.8542 | 0.6443 | 0.5965 | 2.47 | 5.89 | 173,352.10 | 4.15 | 2.36 | 4.74 | 2.73 | 55.96 | 55.03 | 6.96 | 4.34 | 1.27 | 2.96 | 0.4604 | 127.29 | 3.37 | 3.18 | 107.15 | -6.93 | 12.37 | 31.41 |
| DiaSorin SpA | -745.70bn | -745.70bn | 44.83bn | 3.19k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 10.30 | -- | 11.50 | -- | 66.70 | -- | 21.25 | -- | -- | -- | 24.71 | -15.64 | 11.40 | -33.65 | 0.2167 | 16.49 | -- |
| Demant A/S | 22.38bn | 2.65bn | 58.85bn | 21.50k | 22.21 | 6.14 | -- | 2.63 | 11.98 | 10.92 | 101.23 | 43.36 | 0.7192 | 2.03 | 5.68 | 1,034,778.00 | 8.52 | 8.27 | 11.68 | 13.23 | 75.45 | 74.14 | 11.85 | 11.34 | 1.06 | 5.58 | 0.6244 | 0.00 | 13.89 | 10.00 | 12.23 | 6.96 | 8.80 | -- |
| Smith & Nephew plc | 40.39bn | 2.18bn | 77.74bn | 18.00k | 35.56 | 2.09 | 11.27 | 1.92 | 0.2787 | 0.2787 | 5.16 | 4.75 | 0.5535 | 0.7128 | 4.30 | 244,007.60 | 2.99 | 4.10 | 3.62 | 4.99 | 69.04 | 71.27 | 5.41 | 8.02 | 1.11 | 5.48 | 0.4125 | 79.59 | 6.40 | 2.50 | 17.94 | -16.88 | 4.24 | 1.85 |
| BioMerieux SA | 28.38bn | 3.07bn | 87.11bn | 14.65k | 28.50 | 3.01 | 16.56 | 3.07 | 3.46 | 3.46 | 32.04 | 32.80 | 0.7356 | 1.82 | 5.63 | 259,811.60 | 7.71 | 9.30 | 9.57 | 12.31 | 55.72 | 56.51 | 10.48 | 12.38 | 1.20 | 236.14 | 0.1258 | 17.76 | 2.39 | 8.70 | -20.95 | 6.87 | 8.36 | 19.42 |
| Sartorius AG | 24.78bn | 620.42m | 108.02bn | 13.76k | 144.54 | 4.54 | 27.83 | 4.36 | 1.22 | 1.22 | 48.66 | 38.73 | 0.3365 | 1.84 | 9.34 | 227,432.60 | 1.37 | 8.21 | 1.73 | 11.83 | 43.95 | 50.93 | 4.06 | 14.15 | 1.13 | 2.41 | 0.545 | 19.59 | -18.66 | 16.74 | -69.74 | 7.74 | 19.14 | 3.66 |
| Sartorius Stedim Biotech SA | 20.48bn | 1.26bn | 127.01bn | 10.38k | 97.70 | 4.38 | 37.30 | 6.20 | 1.79 | 1.79 | 29.22 | 39.95 | 0.4145 | 1.75 | 8.84 | 257,644.00 | 2.61 | 11.87 | 3.04 | 15.12 | 41.82 | 50.96 | 6.31 | 17.44 | 1.03 | 2.95 | 0.4266 | 18.73 | -20.53 | 18.02 | -64.65 | 8.28 | 21.82 | 3.90 |
| Straumann Holding AG | 19.76bn | 2.46bn | 142.37bn | 11.15k | 57.88 | 9.03 | 39.80 | 7.20 | 1.93 | 1.70 | 15.47 | 12.34 | 0.715 | 1.76 | 4.21 | 222,176.90 | 8.95 | 10.68 | 11.84 | 13.63 | 72.76 | 74.95 | 12.52 | 15.15 | 1.55 | 13.15 | 0.187 | 37.50 | 3.92 | 12.08 | -43.40 | -2.04 | 11.54 | 10.12 |
| Sonova Holding AG | 29.69bn | 4.52bn | 149.02bn | 18.55k | 33.09 | 8.12 | 22.78 | 5.02 | 9.43 | 9.43 | 61.94 | 38.43 | 0.6838 | 2.33 | 6.84 | 204,236.70 | 10.54 | 10.87 | 13.40 | 13.88 | 72.42 | 71.97 | 15.42 | 17.77 | 0.823 | 21.70 | 0.419 | 35.21 | -2.98 | 5.59 | -5.84 | 5.77 | 1.75 | 8.20 |
| Koninklijke Philips NV | 134.52bn | -3.50bn | 176.77bn | 69.28k | -- | -- | 33.67 | 1.31 | -0.4847 | -0.335 | 19.14 | -- | -- | -- | -- | 258,972.70 | -- | 0.3678 | -- | 0.5013 | 42.18 | 43.84 | -2.59 | 0.6049 | -- | 5.35 | -- | -- | 1.92 | 0.0529 | 71.87 | -- | -5.24 | -- |
| Coloplast A/S | 27.03bn | 5.05bn | 187.41bn | 16.25k | 39.43 | 11.20 | 29.55 | 6.93 | 22.61 | 22.61 | 121.01 | 79.62 | 0.5618 | 2.44 | 6.01 | 1,663,692.00 | 10.50 | 16.21 | 14.49 | 22.91 | 67.59 | 67.85 | 18.69 | 21.02 | 0.6637 | 8.49 | 0.5578 | 92.23 | 10.33 | 8.54 | 5.62 | 5.46 | 14.30 | 5.29 |
Data as of Nov 25 2024. Currency figures normalised to Coloplast A/S's reporting currency: Danish Krone DKK
13.77%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fundsmith LLPas of 30 Jun 2024 | 7.66m | 3.65% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 4.51m | 2.15% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 3.03m | 1.44% |
| BlackRock Investment Management (UK) Ltd.as of 31 Oct 2024 | 2.31m | 1.10% |
| BlackRock Fund Advisorsas of 07 Nov 2024 | 2.27m | 1.08% |
| Geode Capital Management LLCas of 21 Nov 2024 | 2.00m | 0.95% |
| Capital International Ltd.as of 30 Sep 2024 | 1.96m | 0.93% |
| Handelsbanken Fonder ABas of 31 Oct 2024 | 1.82m | 0.86% |
| Comgest SAas of 31 Jul 2024 | 1.81m | 0.86% |
| Allianz Global Investors GmbHas of 30 Sep 2024 | 1.58m | 0.75% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
